| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Kalvista Pharmaceuticals, Inc. (KALV) has 12 insiders with recent SEC Form 4 filings, including 0 buys and 12 sells. KALV is classified in the Biotechnology industry within the Health Care sector.
| Role | Insider | Shares | Value | 30d |
|---|---|---|---|---|
| CEO | 462.6K | $12.49M | - | |
| Other | 223.5K | $6.03M | - | |
| Other | 142.5K | $3.85M | - | |
| Other | 100.0K | $2.70M | - | |
| Other | 51.4K | $1.39M | - |
Buys and sells only
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| May 20, 2024 | Audhya Paul K. | Chief Medical Officer | Sale+OE | 13,175 | $11.76 | $154,997.29 | -15.8% | +3.0% | +3.0% | |
| May 20, 2024 | Palleiko Benjamin L46 | Chief Executive Officer | Sale+OE | 21,959 | $11.76 | $258,336.66 | -9.2% | +3.0% | +3.0% | |
| May 20, 2024 | Yea Christopher53 | Chief Development Officer | Sale+OE | 11,610 | $11.76 | $136,585.85 | -12.7% | +3.0% | +3.0% | |
| Feb 20, 2024 | Palleiko Benjamin L46 | CFO, Cbo | Sale+OE | 22,802 | $14.11 | $321,845.67 | -10.9% | -13.9% | -22.4% | |
| Feb 20, 2024 | Audhya Paul K. | Chief Medical Officer | Sale+OE | 14,295 | $14.12 | $201,773.93 | -21.3% | -13.9% | -22.4% | |
| Feb 20, 2024 | Crockett Thomas Andrew72 | CEO | Sale+OE | 24,888 | $14.11 | $351,289.14 | -10.5% | -13.9% | -22.4% | |
| Feb 20, 2024 | Yea Christopher53 | Chief Development Officer | Sale+OE | 12,053 | $14.11 | $170,124.48 | -14.2% | -13.9% | -22.4% | |
| Feb 20, 2024 | Feener Edward P.72 | Chief Scientific Officer | Sale+OE | 28,288 | $14.07 | $397,929.01 | -12.0% | -13.9% | -22.4% | |
| Feb 14, 2024 | Palleiko Benjamin L46 | CFO, Cbo | Sell | 40,855 | $15.01 | $613,204.95 | -20.4% | -13.3% | -33.8% | |
| Feb 14, 2024 | Crockett Thomas Andrew72 | CEO | Sell | 58,356 | $15.01 | $875,882.71 | -24.3% | -13.3% | -33.8% |